Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year

VolumeIssuePage

Issues

Placental expression of proteases and their inhibitors in patients with HELLP syndrome

Stephanie Pildner von Steinburg1 / Achim Krüger2 / Thorsten Fischer1, 3 / Karl-Theodor Mario Schneider1 / Manfred Schmitt1

1Abteilung Perinatalmedizin, Frauenklinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, D-81675 München, Germany

2Institut für Experimentelle Onkologie und Therapieforschung, Technische Universität München, Klinikum rechts der Isar, D-81675 München, Germany

3Klinik für Gynäkologie und Geburtshilfe, Krankenhaus Landshut-Achdorf, D-84036 Landshut, Germany

Corresponding author

Citation Information: Biological Chemistry. Volume 390, Issue 11, Pages 1199–1204, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: 10.1515/BC.2009.123, August 2009

Publication History

Received:
2009-02-06
Accepted:
2009-06-09
Published Online:
2009-08-10

Abstract

In preeclampsia and hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome, impaired trophoblast invasion and excessive fibrin deposition in the placental intervillous space is associated with fetal compromise. However, little information is available whether modulation of placental protease expression – potentially causing impaired trophoblast invasion – is associated with the HELLP syndrome. Total RNA and protein were extracted from placental tissue from 11 females with HELLP syndrome and 8 controls matched for gestational age. mRNA expression of matrix metalloprotease (MMP) -2 and -9, tissue inhibitors of metalloprotease (TIMP) -1, -2, and -3, and urokinase-type plasminogen activator receptor (uPAR) was determined by Northern blotting. Protein expression of MMP-2 and -9, and TIMP-1 and -2 was detected by Western blotting and that of uPA, uPAR, and plasminogen activator inhibitor (PAI) -1 by ELISA. In patients with HELLP syndrome, mRNA expression of MMP-2 and TIMP-2 was decreased, whereas TIMP-1 and -3 levels were unchanged. MMP-9 and uPAR mRNA was undetectable in both groups. Protein expression of all investigated proteolytic factors remained unchanged. Our findings at the mRNA level suggest a decrease in matrix remodeling in placentae from patients with HELLP syndrome compared with control pregnancies, although this is not supported at the protein level.

Keywords: matrix metalloprotease; placenta; preeclampsia; trophoblast invasion; urokinase-type plasminogen activator receptor

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.